AU2008216669B2 - A method for enhancing T cell response - Google Patents

A method for enhancing T cell response Download PDF

Info

Publication number
AU2008216669B2
AU2008216669B2 AU2008216669A AU2008216669A AU2008216669B2 AU 2008216669 B2 AU2008216669 B2 AU 2008216669B2 AU 2008216669 A AU2008216669 A AU 2008216669A AU 2008216669 A AU2008216669 A AU 2008216669A AU 2008216669 B2 AU2008216669 B2 AU 2008216669B2
Authority
AU
Australia
Prior art keywords
dose
cell
use according
doses
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008216669A
Other languages
English (en)
Other versions
AU2008216669A1 (en
Inventor
Adrian Bot
Thomas Kundig
Zhiyong Qiu
Kent Andrew Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of AU2008216669A1 publication Critical patent/AU2008216669A1/en
Application granted granted Critical
Publication of AU2008216669B2 publication Critical patent/AU2008216669B2/en
Priority to AU2014201422A priority Critical patent/AU2014201422B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2008216669A 2007-02-15 2008-02-15 A method for enhancing T cell response Ceased AU2008216669B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014201422A AU2014201422B2 (en) 2007-02-15 2014-03-12 A method for enhancing T cell response

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90198007P 2007-02-15 2007-02-15
US60/901,980 2007-02-15
PCT/US2008/002044 WO2008100598A2 (en) 2007-02-15 2008-02-15 A method for enhancing t cell response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014201422A Division AU2014201422B2 (en) 2007-02-15 2014-03-12 A method for enhancing T cell response

Publications (2)

Publication Number Publication Date
AU2008216669A1 AU2008216669A1 (en) 2008-08-21
AU2008216669B2 true AU2008216669B2 (en) 2013-12-12

Family

ID=39690701

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008216669A Ceased AU2008216669B2 (en) 2007-02-15 2008-02-15 A method for enhancing T cell response

Country Status (9)

Country Link
US (1) US20080199485A1 (https=)
EP (2) EP2481418A1 (https=)
JP (2) JP5755839B2 (https=)
CN (2) CN103736086A (https=)
AU (1) AU2008216669B2 (https=)
CA (1) CA2678353A1 (https=)
ES (1) ES2527412T3 (https=)
MX (1) MX2009008620A (https=)
WO (1) WO2008100598A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
SG162817A1 (en) 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
EP2139992A4 (en) 2007-03-30 2011-08-10 Univ Duke METHOD FOR MODULATING THE ACTIVITY OF A NUCLEIC ACID MOLECULE
US8728465B2 (en) * 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
DE102008061522A1 (de) * 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
US20110257458A1 (en) * 2008-12-24 2011-10-20 Cedars-Sinai Medical Center Method of using tumor cell debris to reduce brain tumor recurrence or growth
IN2012DN02345A (https=) * 2009-09-16 2015-08-21 Univ Duke
AU2010310468A1 (en) 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
ES2769326T3 (es) 2010-02-05 2020-06-25 Univ Cornell Métodos y composiciones para la inmunoterapia contra el cáncer usando células tumorales que expresan la proteína de fusión de flagelina y antígeno asociado al tumor
CA2894511C (en) 2012-12-11 2021-12-07 Albert Einstein College Of Medicine Of Yeshiva University Methods for high throughput receptor:ligand identification
US20150037374A1 (en) * 2013-07-31 2015-02-05 Csl Limited Anti-tumor compositions and uses thereof
WO2015161094A1 (en) 2014-04-16 2015-10-22 Duke University Electrospun cationic nanofibers and methods of making and using the same
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
WO2016180467A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
EA201792501A1 (ru) 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
JP6969848B2 (ja) 2015-07-13 2021-11-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリン組成物
WO2017079537A1 (en) 2015-11-04 2017-05-11 Duke University Polycationic polymers for use in treating and detecting cancer
KR20180105685A (ko) * 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
CN109689096A (zh) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
WO2017201210A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
US12447464B2 (en) 2016-12-22 2025-10-21 Duke University Polycationic microfibers and methods of using the same
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
WO2018124005A1 (ja) * 2016-12-27 2018-07-05 中外製薬株式会社 被験物質の免疫原性を評価する方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
CN111135310B (zh) * 2019-12-24 2021-05-07 江苏省人民医院（南京医科大学第一附属医院） 一种定制化t细胞表位疫苗的双靶向纳米药、其制备方法及应用
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN116262779A (zh) * 2021-12-14 2023-06-16 深圳先进技术研究院 一种单细胞筛选鉴定人乳头瘤病毒特异性tcr的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103636A1 (en) * 2002-06-05 2003-12-18 Agresearch Limited A novel drug dosing regimen
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778879A (en) * 1982-04-20 1988-10-18 Sloan-Kettering Institute For Cancer Research Highly purified human interleukin 2 and method
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
DE4423392A1 (de) 1994-07-04 1996-01-11 Birsner & Grob Biotech Gmbh Verfahren zur Identifizierung antigener Peptide
WO1996027008A2 (de) 1995-02-28 1996-09-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin Mittel zur therapie von tumoren und anderen hyperplasien
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
CN1221349A (zh) * 1996-06-12 1999-06-30 郭亚军 细胞疫苗、免疫治疗以及它们的制备方法
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
ES2265165T3 (es) 1997-07-10 2007-02-01 Mannkind Corporation Dispositivo para inducir una respuesta ltc.
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
PL194804B1 (pl) * 1998-03-16 2007-07-31 Alk Abello As Zrekombinowany alergen, sposób przygotowywania zrekombinowanego alergenu, kompozycja farmaceutyczna oraz zastosowanie zrekombinowanego alergenu do przygotowywania leku do wywoływania odpowiedzi immunologicznej u osobnika i do przygotowywania leku do leczenia, zapobiegania lub osłabiania reakcji alergicznych
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20020165176A1 (en) * 2000-05-01 2002-11-07 Haynes Joel R. Nucleic acid immunization
GB0023008D0 (en) * 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US7252824B2 (en) * 2001-03-07 2007-08-07 Mannkind Corporation Anti-neovasculature preparations for cancer
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
CN101024842A (zh) 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
AU2003270311A1 (en) 2002-09-06 2004-03-29 Mannkind Corporation Epitope sequences
DK1635863T3 (da) * 2003-06-17 2010-11-22 Mannkind Corp Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
AU2004249254B2 (en) 2003-06-17 2010-07-08 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
US6997074B2 (en) 2003-10-30 2006-02-14 Eaton Corporation Prediction of destination gear for progressive shift feature
CA2571168A1 (en) * 2004-06-17 2006-01-26 Mannkind Corporation Mhc i-binding ssx-241-49 variants
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
JP2008526763A (ja) * 2004-12-29 2008-07-24 マンカインド コーポレイション 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法
PL1833506T3 (pl) * 2004-12-29 2016-01-29 Mannkind Corp Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych
EP1838338A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
CA2592972A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103636A1 (en) * 2002-06-05 2003-12-18 Agresearch Limited A novel drug dosing regimen
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens

Also Published As

Publication number Publication date
CN101657213B (zh) 2014-02-26
HK1141251A1 (en) 2010-11-05
WO2008100598A2 (en) 2008-08-21
ES2527412T3 (es) 2015-01-23
JP2014043459A (ja) 2014-03-13
EP2481418A1 (en) 2012-08-01
EP2129389B1 (en) 2014-10-08
CA2678353A1 (en) 2008-08-21
CN103736086A (zh) 2014-04-23
AU2008216669A1 (en) 2008-08-21
CN101657213A (zh) 2010-02-24
HK1139595A1 (en) 2010-09-24
WO2008100598A3 (en) 2008-12-31
EP2129389A2 (en) 2009-12-09
JP2010519205A (ja) 2010-06-03
MX2009008620A (es) 2009-10-22
US20080199485A1 (en) 2008-08-21
JP5755839B2 (ja) 2015-07-29

Similar Documents

Publication Publication Date Title
AU2008216669B2 (en) A method for enhancing T cell response
Kayraklioglu et al. CpG oligonucleotides as vaccine adjuvants
Lahiri et al. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond
Mohan et al. Novel adjuvants & delivery vehicles for vaccines development: a road ahead
Aimanianda et al. Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants
Schellack et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses
JP2025061056A (ja) 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
ES2380796T3 (es) Oligonucleótidos inmunoestimuladores y sus usos.
CA2278594A1 (en) Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination
Song et al. A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity
Akache et al. Adjuvants: engineering protective immune responses in human and veterinary vaccines
Lampe et al. High‐and low‐molecular‐weight chitosan act as adjuvants during single‐dose influenza A virus protein vaccination through distinct mechanisms
O’Hagan et al. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen
EP2046344A2 (en) Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
Ott et al. Development of vaccine adjuvants: a historical perspective
WO2007122392A1 (en) Composition comprising a cytotoxic t-cell - inducing adjuvant
AU2014201422B2 (en) A method for enhancing T cell response
TW201217000A (en) Vaccine compositions based on sticholysin encapsulated into liposomes
HK1174258A (en) A method for enhancing t cell response
HK1139595B (en) A method for enhancing t cell response
Pavlenko et al. Priming of CD8+ T-cell responses after DNA immunization is impaired in TLR9-and MyD88-deficient mice
HK1141251B (en) A method for enhancing t cell response
Liu NanoAPC deliver antigen, IL-2 and co-stimulatory molecules to antigen specific T cells and activate viral specific T cells in chronic infections
EP3033106A1 (en) Immunoadjuvant compositions and uses thereof
AYOUB et al. Workshop S Vaccination and Immunopharmacology

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired